Isofol has entered into a global, exclusive supply and licensing agreement with Merck KGaA and Merck & Cie for the development and commercialisation of arfolitixorin in cancer treatment. Isofol’s supply and licensing agreement with Merck remains in force as long as any of Isofol’s or Merck’s patents remain valid – a term which currently extends, at a minimum to 2038 (and potentially longer in the light of patent applications subsequently submitted). This agreement regulates both the price that Isofol pays for the API (Active Pharmaceutical Ingredient, i.e. the active substance) and future royalties on sales. The patent portfolio comprises several types of patent: substance, formulation, and how they shall be used in the treatment process.